Literature DB >> 30342659

EphA2-positive human umbilical cord-derived mesenchymal stem cells exert anti-fibrosis and immunomodulatory activities via secretion of prostaglandin E2.

Yu-Chieh Wen1, Mao-Kuang Du1, Meng-Wei Li1, Yogi Cheng-Yo Hsuan1, Yu-Chin Su2, Willie Lin3.   

Abstract

OBJECTIVE: Previous study has demonstrated that EphA2 is a biomarker of mesenchymal stem cells (MSCs) from human placenta or umbilical cord and is able to distinguish MSCs from fibroblasts. In this study, we further examine the potential efficacy of EphA2+ human umbilical cord-derived MSCs (hUC-MSCs).
MATERIALS AND METHODS: MSCs specific markers, EphA2 and CD146 expression on the surface of hUC-MSCs were determined by flow cytometry analysis. Quantitative real time polymerase chain reaction was used to examine pro-fibrotic gene expression of TGF-β1-stimulated lung fibroblast (MRC-5 cells). On the other hand, ELISA was used to analyze the content of pro-inflammatory cytokines (TNF-ɑ; and IP-10) in the LPS-activated macrophages culture supernatant.
RESULTS: The pro-fibrotic gene (TGF-β1, CTGF, fibronectin, collagen I and TIMP-1) expression in TGF-β1-activated MRC-5 cells and the pro-inflammatory cytokines (TNF-ɑ and IP-10) in the LPS-activated macrophages culture supernatant were both attenuated when in present of EphA2+ hUC-MSCs. Moreover, once EphA2+ hUC-MSCs treated with prostaglandin E2 specific inhibitor NS-398, both anti-fibrotic and anti-inflammatory effects of EphA2+ hUC-MSCs were abolished.
CONCLUSION: EphA2+ hUC-MSCs possess immunomodulatory and anti-fibrotic properties, and PGE2 plays an important role in these activities. This implies that EphA2+ hUC-MSCs have potentially effectiveness for treatment of acute inflammatory and chronic fibrotic lung diseases.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Anti-fibrosis; EphA2; Immunomodulatory; Mesenchymal stem cells; Prostaglandin E2

Mesh:

Substances:

Year:  2018        PMID: 30342659     DOI: 10.1016/j.tjog.2018.08.020

Source DB:  PubMed          Journal:  Taiwan J Obstet Gynecol        ISSN: 1028-4559            Impact factor:   1.705


  5 in total

1.  Allogeneic human umbilical cord-derived mesenchymal stem cells reduce lipopolysaccharide-induced inflammation and acute lung injury.

Authors:  Shiao-Ya Hong; Sen-Wen Teng; Willie Lin; Cheng-Yi Wang; Hen-I Lin
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

2.  The effects of human umbilical cord-derived mesenchymal stem cell transplantation on endometrial receptivity are associated with Th1/Th2 balance change and uNK cell expression of uterine in autoimmune premature ovarian failure mice.

Authors:  Xueyan Lu; Jingjing Cui; Linlu Cui; Qianqian Luo; Qizhi Cao; Wendan Yuan; Hongqin Zhang
Journal:  Stem Cell Res Ther       Date:  2019-07-22       Impact factor: 6.832

Review 3.  Stem cell therapy for preventing neonatal diseases in the 21st century: Current understanding and challenges.

Authors:  Christopher R Nitkin; Johnson Rajasingh; Courtney Pisano; Gail E Besner; Bernard Thébaud; Venkatesh Sampath
Journal:  Pediatr Res       Date:  2019-05-14       Impact factor: 3.756

4.  hUMSCs regulate the differentiation of ovarian stromal cells via TGF-β1/Smad3 signaling pathway to inhibit ovarian fibrosis to repair ovarian function in POI rats.

Authors:  Linlu Cui; Hongchu Bao; Zhongfeng Liu; Xuejing Man; Hongyuan Liu; Yun Hou; Qianqian Luo; Siyuan Wang; Qiang Fu; Hongqin Zhang
Journal:  Stem Cell Res Ther       Date:  2020-09-07       Impact factor: 6.832

5.  Comparative Proteomic Analysis Identifies EphA2 as a Specific Cell Surface Marker for Wharton's Jelly-Derived Mesenchymal Stem Cells.

Authors:  Ashraf Al Madhoun; Sulaiman K Marafie; Dania Haddad; Motasem Melhem; Mohamed Abu-Farha; Hamad Ali; Sardar Sindhu; Maher Atari; Fahd Al-Mulla
Journal:  Int J Mol Sci       Date:  2020-09-03       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.